INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme
Status:
Active, not recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether the combination of two agents, INC280 and
bevacizumab, is safe and effective when administered to patients with Glioblastoma Multiforme
(GBM) who have progressed after receiving prior therapy or who have unresectable GBM.